Search results for

Wall Street Journal economics writer David Wessel's new book, Red Ink, lays out in unsparing terms the way the U.S. government spends money, who pays what in taxes, and why politicians can't seem to agree on ways to reduce the potentially catastrophic deficit.

The unassuming, 45-year-old Sergio Moro has jailed many of Brazil's rich and powerful, formerly presumed unimpeachable. Moro plays down accolades but some want him to run for president.

The top-ranked U.S. team is returning to the Women's World Cup final for a third straight time after defeating England 2-1 Tuesday. They'll take on either the Netherlands or Sweden on Sunday.

This holiday season, instead of settling for the standard martini, historian Lesley Blume suggests you reach for a taste of bygone cocktail culture. She offers tips for picking the right antique elixir, as well as the original recipe for one of Ernest Hemingway's favorites.

In 2009, when the other Big Three automakers were filing for bankruptcy protection, Ford CEO and auto-industry outsider Alan Mulally helped the company post its first annual profit in four years. In American Icon, journalist Bryce Hoffman explores how Mulally helped Ford avoid the fate of its fellow automakers.

For many young readers, Dahl is a beloved author. But to Lucy Dahl, he's also Dad. "Matilda was one of the most difficult books for him to write," she says. "I think that there was a deep genuine fear within his heart that books were going to go away and he wanted to write about it."

NPR's A Martinez speaks with Ben Rothenberg, co-host of the podcast No Challenges Remaining, about the Australian Open finals.

California holds an open primary Tuesday — meaning candidates from both parties run together with the top two advancing. Candidates are vying to replace the late Sen. Dianne Feinstein.

A top mine safety regulator testified before Congress that no new regulations are needed to protect workers from deadly silica dust, despite an epidemic of advanced black lung disease.

Drugmakers make big profits in the U.S. But many pay taxes far below the 21% corporate tax rate. Pfizer's effective tax rate is so low it's getting a big refund despite booking $59 billion in revenue.